Answer
Limited data suggest that co-administering imiglucerase with Zavesca (miglustat) in type 1 Gaucher disease may decrease miglustat exposure, with approximate reductions of 22% in Cmax and 14% in AUC observed in a small parallel-group study.
Sources for this answer
- Zavesca 100 mg capsules (Great Britain)Janssen-Cilag Ltd (a Johnson & Johnson Company) · emc · SmPC §4.5 Interaction with other medicinal products · Version 30Document updated
Sources checked